CAIV-T

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Influenza

Conditions

Influenza

Trial Timeline

Sep 1, 2000 → May 1, 2002

About CAIV-T

CAIV-T is a phase 3 stage product being developed by Pfizer for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT00192283. Target conditions include Influenza.

What happened to similar drugs?

20 of 20 similar drugs in Influenza were approved

Approved (20) Terminated (1) Active (0)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT00192166Phase 2Completed
NCT00192348Phase 1Completed
NCT00192400Phase 3Completed
NCT00192426Phase 3Completed
NCT00192231Phase 3Completed
NCT00217230Phase 3Completed
NCT00192192Phase 3Completed
NCT00192270Phase 2Completed
NCT00192283Phase 3Completed

Competing Products

20 competing products in Influenza

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 2
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1083.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1083ModernaPhase 3
0
mRNA-1073ModernaPhase 2
0
VAL-506440ModernaPhase 1
0
mRNA-1083ModernaPhase 3
0
mRNA-1083ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
VAL-339851ModernaPhase 1
0
mRNA-1018-H5ModernaPhase 3
0
mRNA-1653ModernaPhase 1
0
mRNA-1030ModernaPhase 2
0
mRNA-1018 for H5N8ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0